Department of Dermatology, Ghent University Hospital, De Pintelaan 185, 9000, Ghent, Belgium,
Arch Dermatol Res. 2013 Dec;305(10):945-50. doi: 10.1007/s00403-013-1418-6. Epub 2013 Oct 6.
An association among the occurrence of antidrug antibodies (ADAs), diminished trough serum drug levels (TSDLs) and non-response or loss of response has been described for several tumor necrosis factor alpha (TNF) blocking agents in a variety of diseases, including psoriasis. In a series of ten psoriasis patients with primary or secondary failure, or adverse reactions during anti-TNF therapy, we measured ADAs and TSDLs in patient serum using radioimmunoassay and ELISA, respectively. By proposing a treatment algorithm derived from research in this field, we show that measuring ADAs and TSDLs in psoriasis patients provides a more structured approach to clinical decision making for psoriasis patients who fail anti-TNF therapy.
在包括银屑病在内的多种疾病中，已有研究描述了针对几种肿瘤坏死因子-α（TNF）拮抗剂的药物抗体（ADA）的出现、低谷血清药物浓度（TSDL）降低与无应答或应答丧失之间的关联。在一组 10 名原发性或继发性治疗失败、或在抗 TNF 治疗期间出现不良反应的银屑病患者中，我们分别使用放射免疫分析和 ELISA 法测量了患者血清中的 ADA 和 TSDL。通过提出源自该领域研究的治疗算法，我们表明，在银屑病患者中测量 ADA 和 TSDL 可更系统地为抗 TNF 治疗失败的银屑病患者提供临床决策。
